Study Comparing iNPWT Dressing and Devices Affect on Bioburden Levels and Skin Condition After Seven Days

Skin Sensitisation Clinical Trial

— HHiNPWT7DC  

Official title:

Healthy Human Study on DeRoyal Incisional Dressing With NPWT Compared Against Standard of Care NPWT Incision Dressing to Investigate Bioburden Levels and Skin Condition After Seven Day Period

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05559697
• Other study ID #: 1139
• Status: Completed
• Phase: N/A
• Start date: February 26, 2024
• Est. completion date: March 7, 2024

Study information

• Verified date: March 2024
• Source: DeRoyal Industries, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Incisional dressings aim to prevent contamination of an incisional wound and protect against skin irritation. Surgeons use incisional negative pressure wound therapy (iNPWT) to manage incisional wounds. This study compares a new dressing designed for use with iNPWT that aims to improve comfort, tolerability, and dressing survivability over the standard of care for iNPWT. Further, no evidence exists that shows NPWT reduces the bacterial burden on the skin. This study will compare the incidence of skin irritation, dressing damage or lift, and changes in bacteria flora on healthy volunteer skin.

Description:

The study compares the DeRoyal Negative Pressure Wound Therapy Incisional Dressing used with the DeRoyal Disposable NPWT device (experimental) to the market leader NPWT Incision Dressing system (control) over seven days to compare skin flora rebound, dressing degradation, skin irritation, and overall user experience. The protocol simulates the preparation of both knees for total knee replacement surgery (Day 0). After prepping the knee (shaving and chlorohexidine gluconate scrub), research personnel will swab the knee cap for an initial bioburden assessment. One knee is randomized to receive the experimental intervention, and the other knee receives the control intervention. Participants will wear both dressings for seven days documenting interruptions in the NPWT for activities of daily living, system-related discomfort, self-assessment of dressing damage, and tolerance for each system. Participants return to the clinic after seven days. First, research personnel will document each dressing's condition with photography and an assessment scale. The research staff will remove dressings under aseptic conditions, photograph each knee, and swab each for bioburden analysis. A blinded researcher will assess each knee for skin redness, irritation, blistering, or other skin adverse event and overall appearance using an adapted FDA scale for skin irritation. The participant's participation in the trial ends at this point. The resulting data will be analyzed using statistical methods to inform on differences in bioburden present under each dressing, the incidence of skin irritation or other adverse events, dressing survivability, discomfort differences, and tolerance of each system.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: March 7, 2024
• Est. primary completion date: March 7, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 40 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Provision of signed and dated informed consent form

2. Stated willingness to comply with all study procedures and availability for the duration of the study

3. Male or female, aged 40 to 80 years of age

4. In good general health as evidenced by medical history

5. Healthy skin located across both knees at the dressing site location

6. No history of chronic knee pain

7. For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study

8. Agreement to adhere to Lifestyle limitations throughout study duration

9. Ability to understand and write in English

Exclusion Criteria:

1. The presence of localized skin conditions, such as scaring, local discoloration, tattoos, freckles, birthmarks, moles or other skin abnormality, that may impair assessment of skin as judged by the clinician

2. Known allergic reactions to components of the Prevena Dressing, DeRoyal Incisional dressing, Hibiclens or a history of skin irritation allergic reaction to chlorohexidine, isopropyl alcohol, chlorohexidine gluconate, or silver.

3. History of skin irritation, skin sensitivity or skin disease including psoriasis, eczema, atopic dermatitis, and skin cancer.

4. Pregnant or lactating female

Lifestyle Limitations during the Study:

During this study, participants are asked to adhere to following lifestyle limitations:

• Abstain from strenuous exercise activity such as running, playing contact sports, biking, and yard work. Participants may walk at a slow pace.

• To keep both dressings shielded from sunlight and fluorescent light (e.g. wear pants or cover with elastic bandage)

• To protect dressing and not expose to high moisture/water submersion environment.

• Limit showering to once per day

• To keep the NPWT devices on and connected to dressing at all times except when showering and changing clothes

Related Conditions & MeSH terms

• Skin Diseases
• Skin Sensitisation

Intervention

Device:
• Sponsor incisional negative pressure wound therapy device and dressing
A sponsor incisional dressing placed on the knee and connected to a sponsor disposable negative pressure therapy device
• Standard of Care incisional negative pressure wound therapy system
The control incisional negative pressure wound therapy system represents the standard of care system and market leader. It consists of a disposable negative pressure therapy device and incisional dressing.

Locations

Country	Name	City	State
United States	Lincoln Memorial University; Cedar Bluff Campus	Knoxville	Tennessee

Sponsors (2)

Lead Sponsor	Collaborator
DeRoyal Industries, Inc.	Lincoln Memorial University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Skin Irritation Score	Skin assessment is performed utilizing the Federal Drug Administration's Combined Evaluation of Skin Irritation and Sensitization utilized by the FDA for assessing topical delivery systems (https://www.fda.gov/media/117569/download). The assessments include photographs of the skin to document any noticeable differences between the two interventions visually.; The dermal response score has eight levels between 0 and 7: 0:No evidence of irritation and 7: Strong reaction spreading beyond the dressing. Refer to the linked document for the entire scale; The Other Effects Score (if present) has six characteristics associated with a numerical value: A(0): Slightly glazed appearance, B(1): Markedly glazed appearance, C(2): Glazing with peeling & cracking, F(3): Glazing with fissures, G(3): Film of dried serous exudates covering all or part of the dressing site, H(3): Small petechial erosions and scabs.; The sum of the two scores represents the total irritation score.	Day 1 (Baseline) and Day 7
Secondary	Change in skin flora bioburden	Sterile skin swabs will be performed on approximately a 1 by 1 inch area of the knee cap on day 1 after skin prep and day 7 after removal of the dressings. Swabs will undergo bioburden testing to recover any organisms present on the skin. Day 0 assessments confirms the efficacy of the skin preparation procedure and day 7 measurements reflect rebound of skin flora under the two interventions.	Performed Day 1 (Baseline) and Day 7
Secondary	Dressing Discomfort Assessment	Healthy volunteer self assessment using a visual analogue scale to rate pain/discomfort experienced during study. Volunteers will mark on a 10 cm line their assessment of discomfort. No pain or discomfort indicated by a score of 0. Extreme pain or discomfort indicated by a score of 10.	Assessment performed once a day for 7 days by participant
Secondary	Intervention Tolerance Assessment	Healthy volunteer self assessment using a visual analogue scale to rate tolerance of each intervention during the study. Tolerance includes assessment of sound and impact on daily life. Volunteers will mark on a 10 cm line their assessment of discomfort. A score of 0 indicates intervention completely tolerable, does not interfere with daily living. A score of 10 indicates intervention completely intolerable, makes daily living impossible.	Assessment performed once a day for 7 days by participant
Secondary	Change in Dressing Lift Incidence (Participant Assessment)	Calculate incidence rate of any dressing lift (lift or rolling) that occurs with each dressing	Assessment performed once a day by participant for Days 1 - 6. Clinician performs assessment at Day 7
Secondary	Change in Dressing Lift Incidence (Clinician Assessment)	Calculate incidence rate of any dressing lift (lift or rolling) that occurs with each dressing	Clinician performs assessment at Day 7
Secondary	Change in Dressing Lift Percentage (Participant Assessment)	The participant or clinician research uses a dressing diagram to indicate dressing lift or damage. Final analysis will calculate the percent area where damage occurred. A separate photograph of the dressing will confirm final assessment.	Assessment performed once a day by participant for Days 1 - 6.
Secondary	Change in Dressing Lift Percentage (Clinician Assessment)	The participant or clinician research uses a dressing diagram to indicate dressing lift or damage. Final analysis will calculate the percent area where damage occurred. A separate photograph of the dressing will confirm final assessment.	Clinician performs assessment at Day 7

External Links

•   Guidance Document defining Skin irritation and sensitization scale used as primary outcome